264.37

0.52% -1.488

Praxis Precision Medicines Inc (PRAX)

Overview News Price History Option Chain Financials Discussions Forecast

Praxis Precision Medicines Inc stock is traded at $264.37, with a volume of 252.45K. It is down -0.52% in the last 24 hours and up +43.64% over the past month. Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Previous Close:

$265.86

Open:

$270.31

24h Volume:

252.45K

Relative Volume:

0.25

Market Cap:

$6.62B

Revenue:

$1.77M

Net Income/Loss:

$-123.74M

P/E Ratio:

-28.83

EPS:

-9.17

Net Cash Flow:

$-95.21M

1W Performance:

-1.04%

1M Performance:

+43.64%

6M Performance:

+515.52%

1Y Performance:

+277.20%

1-Day Range:

$262.31

$275.31

1-Week Range:

$262.31

$282.99

52-Week Range:

$26.70

$282.99

Praxis Precision Medicines Inc Stock (PRAX) Company Profile

Name

Praxis Precision Medicines Inc

Sector

Healthcare (1136)

Industry

Biotechnology (632)

Phone

617-300-8460

Address

99 HIGH STREET, 30TH FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PRAX's Discussions on Twitter

Compare PRAX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRAX Praxis Precision Medicines Inc	264.53	6.65B	1.77M	-123.74M	-95.21M	-9.17
VRTX Vertex Pharmaceuticals Inc	446.17	114.05B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	746.85	78.80B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	396.35	51.80B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	850.56	53.08B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	164.24	42.33B	447.02M	-1.18B	-906.14M	-6.1812

Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-19-25	Initiated	BTIG Research	Buy
Jun-02-25	Resumed	Oppenheimer	Outperform
May-07-25	Initiated	Chardan Capital Markets	Buy
Mar-03-25	Reiterated	H.C. Wainwright	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Aug-05-24	Initiated	Oppenheimer	Outperform
Jun-24-24	Initiated	Needham	Buy
Jun-18-24	Initiated	Guggenheim	Buy
May-01-24	Initiated	Robert W. Baird	Outperform
Sep-19-23	Initiated	Truist	Buy
Jun-06-22	Downgrade	Wedbush	Outperform → Neutral
Dec-16-21	Initiated	H.C. Wainwright	Buy
Aug-26-21	Initiated	BofA Securities	Buy
Apr-26-21	Initiated	William Blair	Outperform
Nov-11-20	Initiated	Wedbush	Outperform
Nov-10-20	Initiated	Cowen	Outperform
Nov-10-20	Initiated	Evercore ISI	Outperform
Nov-10-20	Initiated	Piper Sandler	Overweight

View All

Praxis Precision Medicines Inc Stock (PRAX) Latest News

04:36 AM

Why Praxis Precision Medicines Inc. stock could be next big winner2025 Fundamental Recap & AI Enhanced Trading Signals - Улправда

04:36 AM

Dec 16, 2025

Medical Stocks To Follow NowDecember 5th - MarketBeat

Dec 16, 2025

Praxis Precision Medicines stock hits 52-week high at 279.0 USD - Investing.com India

Dec 16, 2025

Dec 15, 2025

Has Praxis Precision Medicines Rally Gone Too Far or Is the Market Still Missing Something - Yahoo Finance

Dec 15, 2025

Oppenheimer Maintains Praxis Precision Medicines (PRAX) Outperform Recommendation - Nasdaq

Dec 15, 2025

Oppenheimer Raises Price Target for Praxis Precision Medicine (P - GuruFocus

Dec 15, 2025

Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month HighWhat's Next? - MarketBeat

Dec 15, 2025

Oppenheimer Adjusts Praxis Precision Medicines PT to $750 From $250, Maintains Outperform Rating - marketscreener.com

Dec 15, 2025

Praxis Precision Medicines stock hits 52-week high at 279.0 USD By Investing.com - Investing.com South Africa

Dec 15, 2025

Praxis Precision Medicines stock price target raised to $750 from $250 at Oppenheimer - Investing.com Nigeria

Dec 15, 2025

Dec 14, 2025